Sorrento Therapeutics, Inc.
SRNE
SRNE was delisted on the 22nd of February, 2023.
231 hedge funds and large institutions have $641M invested in Sorrento Therapeutics, Inc. in 2021 Q1 according to their latest regulatory filings, with 45 funds opening new positions, 72 increasing their positions, 67 reducing their positions, and 31 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
93% more call options, than puts
Call options by funds: $75.7M | Put options by funds: $39.3M
45% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 31
18% more capital invested
Capital invested by funds: $541M → $641M (+$100M)
5% more funds holding
Funds holding: 219 → 231 (+12)
7% more repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 67
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$18.9M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$13.1M |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
+$11.2M |
| 4 |
JP Morgan Chase
New York
|
+$10.4M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$5.51M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$30.5M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$18.5M |
| 3 |
Goldman Sachs
New York
|
-$13.2M |
| 4 |
Morgan Stanley
New York
|
-$12.1M |
| 5 |
Jane Street
New York
|
-$9.23M |
SRNE Hedge Fund Activity: Q1 2021 in Review
231 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Sorrento Therapeutics, Inc. (SRNE) for Q1 2021, worth a combined $641M — up 18% from $541M a quarter earlier.
Buyers outnumbered sellers: 45 funds opened new SRNE positions and 31 closed out — a net gain of 14 holders — while 72 added to existing stakes and 67 trimmed.
The largest buyer was BlackRock, adding an estimated $18.9M. The largest seller was State Street, cutting an estimated $30.5M.
- 231 institutional investors held Sorrento Therapeutics, Inc. (SRNE) as of Q1 2021, up from 219 in Q4 2020.
- Funds reported $641M of Sorrento Therapeutics, Inc. stock for Q1 2021, up 18% quarter-over-quarter.
- 45 funds opened new Sorrento Therapeutics, Inc. positions in Q1 2021 and 31 closed out, a net change of +14 holders.
- The largest Sorrento Therapeutics, Inc. buyer in Q1 2021 was BlackRock, an estimated $18.9M added.
- The largest Sorrento Therapeutics, Inc. seller in Q1 2021 was State Street, an estimated $30.5M sold.
Based on aggregated 13F filings for Q1 2021.